학술논문
Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology
Document Type
Original Paper
Author
Hirose, Takeshi; Ito, Mamoru; Tsuchihashi, Kenji; Ozaki, Yukinori; Nishio, Hiroshi; Ichihara, Eiki; Miura, Yuji; Yano, Shingo; Maruyama, Dai; Yoshinami, Tetsuhiro; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Baba, Eishi; Ochi, Nobuaki; Kubo, Toshio; Uchino, Keita; Kimura, Takahiro; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi; Endo, Makoto
Source
International Journal of Clinical Oncology. :1-7
Subject
Language
English
ISSN
1341-9625
1437-7772
1437-7772
Abstract
Background: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, “Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?” and CQ #2, “Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?”.Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019. Two reviewers assessed the extracted papers and analyzed overall survival (OS), febrile neutropenia (FN) incidence, infection-related mortality, quality of life (QOL), and pain.Results: Twenty-five English and five Japanese articles were identified for CQ #1. After screening, a cohort study of vincristine, ifosfamide, doxorubicin, and etoposide chemotherapy with 851 patients was selected. Incidence of FN was 60.8% with G-CSF and 65.8% without; statistical tests were not conducted. Data on OS, infection-related mortality, QOL, or pain was unavailable. Consequently, CQ #1 was redefined as a future research question. As for CQ #2, we found two English and five Japanese papers, of which one high-quality randomized controlled trial on G-CSF use in intensified chemotherapy was included. This trial showed trends toward lower mortality and a significant increase in event-free survival for 2-week interval regimen with the G-CSF primary prophylactic use compared with 3-week interval.Conclusion: This review indicated that G-CSF’s efficacy as primary prophylaxis in Ewing sarcoma, except in children, is uncertain despite its common use. This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma.